Which hip cartilage problems are suitable for this injection?

ChondroFiller injection is designed for a specific type of hip cartilage problem: a focal area of full-thickness damage, graded ICRS III or IV, on the acetabular surface or femoral head. The two most common causes are femoroacetabular impingement (FAI) — where repeated mechanical conflict between the femoral head and acetabular rim abrades the cartilage — and post-traumatic injury following a fracture or significant hip trauma. Defects in the range of roughly 2–6 cm² are most amenable to treatment: contained enough that the surrounding cartilage can provide a stable border for the scaffold to integrate against, yet substantial enough to produce the joint symptoms that bring patients to clinic.

Suitability is not determined at a consultation alone. A pre-injection MRI is essential before any appointment proceeds — it maps the precise size and depth of the defect, assesses subchondral bone integrity beneath it, and confirms that the cartilage surrounding the damaged zone is healthy enough to support scaffold integration. Without that information, it is not possible to judge whether the treatment has a viable environment to work within.

This is an outpatient injection, not a surgical procedure — no theatre, no general anaesthetic, no hospital admission. That distinction carries real weight for patients weighing this against arthroscopic treatment or hip resurfacing.

Patients with widespread bone-on-bone degeneration across the whole joint are unlikely to be suitable candidates, though clinical judgement governs each case individually. The injection pathway does not apply the same rigid Tönnis-grade thresholds that surgical cohort criteria imposed, and no published age ceiling applies to the injection route.

What the ChondroFiller injection does inside the hip joint

Once injected, ChondroFiller behaves differently from a conventional filler or lubricant. The material — a purified Type I collagen hydrogel — arrives as a liquid and gels within minutes inside the defect, conforming precisely to its shape and anchoring within the damaged zone rather than dispersing into the joint fluid.

What happens next is the core of the mechanism: acellular matrix-induced chondrogenesis. The gelled scaffold acts as a structured framework that draws the patient's own progenitor cells — from the surrounding synovial tissue and from the subchondral bone beneath the defect — into the collagen matrix. Those recruited cells progressively remodel the scaffold into hyaline-like repair tissue over the following months. The product introduces no living cells and no donor tissue; the biological work is done entirely by the patient's own repair cells working within a structure the collagen provides.

An ex vivo osteochondral study published in 2025 confirmed this process is measurable rather than theoretical: ChondroFiller-treated samples showed a 2.4-fold increase in DNA content by day 14, demonstrating active cell migration into the scaffold in the early weeks after placement.

Repair tissue does not mature overnight. Clinical improvement and imaging changes tend to emerge gradually between three and six months, reflecting the time needed for meaningful biological remodelling — a detail worth setting out clearly so expectations are grounded in how the process actually works.

Why ultrasound guidance is non-negotiable for hip placement

The hip is not a forgiving joint for blind needle placement. The anterior joint capsule sits 4–8 cm below the skin surface — considerably deeper than the knee or shoulder — and the surrounding neurovascular anatomy leaves little margin for error. The femoral artery runs approximately 1.9 cm medial to the needle path; the femoral vein lies roughly 1.7 cm medial; the femoral nerve sits around 2.3 cm lateral. The lateral circumflex femoral artery crosses the anterior capsule at a position that varies between individuals and cannot be reliably predicted from surface landmarks alone.

That geometry explains a number-that matters: a 2016 systematic review by Hoeber et al., drawing on 120 citations, found that landmark-guided hip injections achieve accurate intra-articular placement in only 72% of cases (95% CI 56–85%). Image-guided techniques, by contrast, reach close to 100% accuracy (95% CI 98–100%), a difference significant at p<0.0001. For a treatment whose effect depends entirely on the scaffold gel reaching and conforming to the cartilage defect, a roughly one-in-four miss rate under landmark guidance is not an acceptable baseline.

Ultrasound guidance solves this by keeping the needle tip visible throughout the approach. The clinician can track the needle as it advances through soft tissue, confirm placement within the joint space before delivering any material, and observe the gel as it is expressed — adjusting in real time if the distribution is uneven. That level of control is especially relevant for a collagen hydrogel: once it sets, the position is fixed.

Technique sensitivity is real. The same product in different hands, placed with or without image guidance, can produce materially different outcomes — which is why the method of delivery is not a secondary consideration. Professor Paul Y. F. Lee, who introduced ChondroFiller injection in the UK, has described precision of placement as central to the clinical result rather than incidental to it.

Candidacy assessment: what the consultation and MRI are looking for

The most common question at consultation is whether the joint is too damaged — and the honest answer is that the threshold is more nuanced than a single scan grade suggests.

The clearest published signal comes from Mazek et al. 2021 (JHPS), a 26-patient arthroscopic cohort in which patients with Tönnis Grade 2–3 osteoarthritis achieved poor results after ChondroFiller gel treatment. That finding matters, but it requires careful interpretation: the Tönnis cut-off emerged from a surgical cohort operating under different delivery constraints. The injection-route pathway does not apply the same hard threshold. A patient with more advanced background wear is not automatically excluded — joint health is read in context, and clinical judgement governs each individual case.

What MRI contributes to that judgement is specific. Beyond confirming defect dimensions (already established as part of the pre-procedure workup), the scan assesses two variables that bear directly on candidacy regardless of delivery route: the integrity of the subchondral bone plate beneath the defect, and the condition of the surrounding articular cartilage. Cystic change or significant bone loss at the defect base is a genuine complicating factor; a defect surrounded by severely degraded cartilage offers less stable ground for scaffold integration. These are the findings that may shift a case away from the injection pathway — not a Tönnis grade read in isolation.

Age, by contrast, is not a selection criterion. No published evidence establishes an upper age limit for the injection route; suitability turns on joint condition rather than patient years. Practical contraindications at the time of treatment include active infection in or near the hip and current use of high-dose corticosteroid.

Candidacy is assessed individually at consultation — not against a fixed protocol, but by weighing all of these factors together.

ChondroFiller injection vs hip resurfacing: where it sits on the treatment spectrum

Hip resurfacing is a major operation — performed under general or spinal anaesthesia, involving preparation of the bone surfaces, implant fixation, and a rehabilitation programme measured in months. It is the right answer for some patients, and nothing about the injection pathway should obscure that.

ChondroFiller injection occupies a structurally different position on that spectrum. The collagen scaffold is placed into the existing defect in an outpatient setting under local anaesthetic. No bone is removed; no implant is fixed. The procedure is additive — the gel conforms to what is already there rather than replacing the anatomy beneath it.

That distinction also separates it from symptomatic options such as corticosteroid or hyaluronic acid injections, which address pain and inflammation without targeting tissue repair. ChondroFiller injection sits a rung above those on the intervention ladder: the intent is structural — to recruit the patient's own progenitor cells and support progressive repair of the defect over months — rather than to suppress symptoms while underlying damage continues.

For patients with a focal defect in an otherwise reasonably preserved joint, this pathway may delay or avoid the need for resurfacing or arthroplasty. Some clinicians combine ChondroFiller with a hydrogel cushioning agent such as Arthrosamid, though the two work through distinct mechanisms — one a regenerative scaffold, the other a permanent filler — and should not be conflated as the same type of intervention.

Where degeneration is diffuse and the joint surfaces are in end-stage contact throughout, resurfacing or arthroplasty is the more appropriate clinical conversation.

Recovery, realistic timelines, and where to be assessed

After injection, protected weight-bearing — typically with crutches — is standard for one to six weeks. The reason is mechanical: a 2024 in-vitro study confirmed that ChondroFiller does not meaningfully shield opposing cartilage under cyclic loading in its early phase, before stable scaffold filling is achieved. Loading the joint fully during that window risks disrupting the gel before the patient's own cells can colonise it.

Repair tissue then matures progressively over three to six months. There is no immediate pain relief — the scaffold is building structure, and functional improvement follows that biological timeline rather than an anaesthetic one.

The clearest hip-specific outcome anchor is from Mazek et al. 2021: suitable candidates achieved a mean modified Harris Hip Score improvement of approximately 30 points over 12 to 60 months. In everyday terms, that scale of change typically marks the difference between restricted daily activity and a return to low-impact sport or comfortable walking. The caveat matters: those figures come from an arthroscopic surgical cohort, not the outpatient injection setting, and should not be read as a direct prediction for injection patients. No randomised trial comparing ultrasound-guided hip injection with arthroscopy or resurfacing currently exists, and long-term hip data beyond five years is absent.

Taken together, the patients most likely to benefit are those with a focal, contained defect in a joint with reasonably preserved cartilage elsewhere — the anatomy where the scaffold has stable ground to work from and genuine room to make a functional difference. That is the clinical profile worth bringing to an assessment.

Liquid Cartilage™ / ChondroFiller injection is delivered in the UK at the London Cartilage Clinic on Harley Street. Assessment appointments are bookable via londoncartilage.com.

1. [1] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y